The FDA is investigating reports that the thinner design of next-generation drug-eluting stents, including Boston Scientific’s (NYSE:BSX) Ion and Promus models, might be prone to deforming after implantation.
At least two studies and one case study presented at a recent cardiology conference reported incidents in which either a Boston Scientific Ion or Promus stent deformed after it was deployed inside a coronary artery.